Rating Overview and Context
On 22 September 2025, MarketsMOJO revised Makers Laboratories Ltd’s rating from 'Sell' to 'Strong Sell', reflecting a significant deterioration in the company’s overall investment appeal. The Mojo Score dropped by 10 points, from 31 to 21, signalling heightened concerns about the stock’s fundamentals and market prospects. This rating indicates that the stock is expected to underperform the broader market and peers in the Pharmaceuticals & Biotechnology sector over the medium term.
It is important to note that while the rating change occurred in September 2025, all financial data, returns, and fundamental indicators referenced here are current as of 30 January 2026. This ensures investors receive an up-to-date assessment of the company’s position.
Here’s How Makers Laboratories Ltd Looks Today
As of 30 January 2026, Makers Laboratories Ltd remains a microcap player within the Pharmaceuticals & Biotechnology sector, grappling with multiple challenges that justify its 'Strong Sell' rating. The company’s Mojo Score of 21.0 and corresponding grade of 'Strong Sell' reflect a combination of weak quality, expensive valuation, flat financial trends, and mildly bearish technical indicators.
Quality Assessment
The company’s quality grade is below average, primarily due to its weak long-term fundamental strength. Over the past five years, Makers Laboratories has experienced a compound annual growth rate (CAGR) decline of -19.06% in operating profits. This negative growth trajectory highlights persistent operational difficulties and an inability to expand profitability sustainably.
Additionally, the average Return on Equity (ROE) stands at a modest 2.20%, signalling low profitability relative to shareholders’ funds. Such a low ROE suggests that the company is not efficiently generating returns on invested capital, which is a critical concern for investors seeking value creation.
Valuation Considerations
Despite the weak fundamentals, Makers Laboratories is currently trading at a very expensive valuation. The stock’s Price to Book (P/B) ratio is approximately 1, which is high relative to its peers and historical averages, especially given the company’s flat financial performance and negative profit trends.
Over the past year, the stock has delivered a negative return of -26.14%, underperforming the broader market benchmark, the BSE500, which has generated a positive return of 7.76% over the same period. This divergence indicates that the market is pricing in significant risks and uncertainties surrounding the company’s future earnings potential.
Financial Trend Analysis
The financial grade for Makers Laboratories is flat, reflecting stagnation rather than growth or decline in recent quarters. The company reported flat results in September 2025, with no key negative triggers identified at that time. However, the overall profit trend remains concerning, with a reported profit decline of -100.4% over the past year, indicating a severe erosion of earnings power.
This flat financial trend, combined with weak profitability metrics, suggests limited near-term catalysts for a turnaround, reinforcing the cautious stance embedded in the 'Strong Sell' rating.
Technical Indicators
From a technical perspective, the stock exhibits a mildly bearish grade. While the one-day price change on 30 January 2026 was a positive 2.13%, short-term movements have been mixed. The stock’s performance over one month shows a gain of 9.23%, but this is offset by declines over three months (-2.12%) and six months (-18.87%). The year-to-date return is a modest +3.68%, yet the one-year return remains deeply negative at -26.14%.
These mixed technical signals suggest that while there may be occasional short-term rallies, the overall trend remains downward, consistent with the broader fundamental challenges.
Market Performance and Peer Comparison
Makers Laboratories has notably underperformed the market and its sector peers over the last year. While the BSE500 index has returned 7.76%, the stock’s negative returns and deteriorating fundamentals highlight its relative weakness. Investors should be cautious, as the company’s microcap status and expensive valuation increase the risk profile.
Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?
- - Building momentum strength
- - Investor interest growing
- - Limited time advantage
What the Strong Sell Rating Means for Investors
For investors, the 'Strong Sell' rating on Makers Laboratories Ltd serves as a clear cautionary signal. It suggests that the stock is expected to underperform significantly relative to the market and sector peers, driven by weak profitability, expensive valuation, and lacklustre financial trends.
Investors should carefully consider the risks associated with holding or acquiring this stock, particularly given its microcap status and the absence of clear catalysts for improvement. The rating advises a defensive approach, favouring capital preservation over speculative exposure.
In summary, the current rating reflects a comprehensive evaluation of four key parameters:
- Quality: Below average, with declining operating profits and low ROE.
- Valuation: Very expensive relative to fundamentals and peers.
- Financial Trend: Flat, with recent profit declines and no significant positive triggers.
- Technicals: Mildly bearish, with mixed short-term price movements but a negative longer-term trend.
These factors collectively underpin the 'Strong Sell' recommendation, signalling that investors should approach Makers Laboratories Ltd with caution and consider alternative opportunities with stronger fundamentals and more attractive valuations.
Looking Ahead
While the current outlook remains challenging, investors should monitor any changes in the company’s operational performance, sector dynamics, and valuation metrics. Improvements in profitability, a more reasonable valuation, or positive technical signals could warrant a reassessment of the rating in the future.
Until such developments materialise, the prudent stance is to heed the 'Strong Sell' rating and prioritise risk management in portfolio construction.
Unlock special upgrade rates for a limited period. Start Saving Now →
